EpiCept is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment and pain management. The Company possesses a cancer product, Ceplene®, approved in the European Union and a deep and balanced pipeline of three major clinical product candidates, including:
- AmiKet™ (formerly known as EpiCept™ NP-1), a pain medication that has completed Phase II clinical trials.
- Crolibulin™, an apoptosis inducer for solid vascularized tumors that is currently in Phase I clinical trials.
- Azixa™, an oncology compound that is currently in Phase II trials for brain cancer.
EpiCept is headquartered in Tarrytown, New York.
EpiCept is listed on both the Nasdaq OMX Stockholm Exchange and the OTCQX under the symbol “EPCT”.
Vision and Mission
EpiCept’s vision is to create and develop products that make a meaningful difference in people’s lives. As such, it is dedicated to successfully increasing the life span of cancer patients and continually improving the quality of life of pain sufferers.
Our mission is the relentless pursuit of satisfying unmet medical needs with pharmacologic agents that are based on sound scientific findings, demonstrated safety and efficacy, and unique and proven technologies. We are focused on advancing a pipeline of world-class products that treat malignant diseases and moderate-to-severe pain.
EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company’s pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies. The Company’s product Ceplene®, when used concomitantly with low-dose IL-2 is intended as remission maintenance therapy in the treatment of AML for adult patients who are in their first complete remission. The Company sold all of its rights to Ceplene® in Europe and certain Pacific Rim countries and a portion of its remaining Ceplene® inventory to Meda AB in June 2012. Ceplene® is licensed to MegaPharm Ltd. to market and sell in Israel and EpiCept has retained its rights to Ceplene® in all other countries, including countries in North and South America. The Company has other oncology drug candidates in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.
EpiCept seeks to generate significant value for its shareholders by developing effective drug candidates, including new chemical entities and new uses for existing therapies, advancing them into late-stage clinical development and then seeking marketing approval either alone or in conjunction with strategic partners.